Tumour necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) is a TNF ligand superfamily member that mediates pleiotropic effects on a variety of cells via its receptor, fibroblast growth factor inducible 14 (Fn14). The TWEAK/Fn14 pathway appears to have a physiological role in the regulation of tissue repair after injury, when Fn14 expression is highly induced.
1 Fn14 can be expressed by many cell types, including epithelial, mesenchymal and endothelial cells, and progenitor cells of the mesenchymal lineage. 2 3 Activating Fn14 can have a number of effects, depending on cell type and context, including proangiogenic effects and induction of fibroblast-like synoviocytes (FLS) to produce proinflammatory cytokines and chemokines, such as interleukin (IL)6, IL8 and Regulated on Activation, Normal T Expressed and Secreted (RANTES). 3 4 TWEAK may also promote bone and cartilage destruction through inhibition of chondrogenesis and osteogenesis and promotion of osteoclastogenesis. 2 These data raise the possibility that TWEAK may contribute to chronic synovitis, a notion supported by the observation that TWEAK expression is dramatically elevated in the murine collagen-induced arthritis (CIA) model of arthritis. Blocking TWEAK signalling reduced the severity of arthritis in this model, and diminished synovial inflammation, vascularity, and cartilage and bone destruction. 2 5 However, very little is known about the role of the TWEAK/Fn14 pathway in human inflammatory arthritis. To address this issue, we examined the expression of TWEAK and Fn14 in synovial tissue (ST) of patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA), in newly diagnosed, previously untreated patients with RA, and in patients with RA on methotrexate before and after treatment with infliximab.
PATIENTS AND METHODS Patients and synovial tissue acquisition
For a comparative analysis of TWEAK and Fn14 expression, ST biopsies were obtained by arthroscopy from 13 patients with RA and 16 patients with PsA with clinically active arthritis. ST biopsies from a second cohort of 13 patients with RA on methotrexate (MTX) therapy were obtained from the same joint before and 4 weeks after the initiation of infliximab (IFX) therapy (IFX 3 mg/ kg, administered intravenously at baseline and 2 weeks later). 6 Additionally, ST biopsies were obtained from 6 patients newly diagnosed as having RA who had not been treated with any disease-modifying antirheumatic drug (DMARD). All patients with RA met the 1987 revised criteria of the American College of Rheumatology for the diagnosis of RA. 7 All patients with PsA fulfilled the CASPAR (for ''ClASsification of Psoriatic ARthritis'') group criteria, 8 and had active joint and skin disease at the time of arthroscopy. ST biopsies were obtained by arthroscopy from an actively inflamed knee, ankle or wrist joint under local anaesthesia. 9 Biopsies were obtained from six or more sites in each joint. ST biopsies were immediately embedded in TissueTek OCT (Miles Diagnostics, Elkhart, Indiana, USA), snap frozen in liquid nitrogen and stored at 280uC, as previously described in detail. 9 10 All patients provided their written informed consent and patient clinical and demographic data were obtained before arthroscopy. This study was approved by the local medical ethics committee.
Immunohistochemistry and digital image analysis
ST samples were cut with a cryostat (5 mm), fixed with acetone, and endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide. Specific monoclonal antibodies were used to detect TWEAK (clone P3H8) and Fn14 (clone P2D3) (both from Biogen Idec, Cambridge, Massachusetts, USA). Bound antibody was detected with a three-step immunoperoxidase method using a biotinylated tyramine amplification method.
11 Stained sections were then randomly analysed using digital image analysis (DIA), as previously described in detail. 12 
Statistical analysis
To compare the differences in expression of TWEAK and Fn14 between groups the Mann-Whitney U test for non-parametric data was used. Correlations were assessed using the Spearman rank correlation coefficient. Serial biopsies were evaluated using the Wilcoxon signed rank test. A p value of ,0.05 was considered statistically significant. Table 1 shows the patient characteristics of the first patient cohort (13 patients with RA and 16 with PsA) who were used for cross sectional comparison. All these patients were treated with methotrexate; there was a trend towards slightly higher dosages in RA, but this difference was not statistically significant. In both groups one patient was also treated with prednisolone 10 mg daily. Most patients had longstanding disease and displayed comparable erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels, indicating similar degrees of inflammatory activity. In RA and PsA ST, strong expression of TWEAK was observed in the intimal lining layer and the synovial sublining, including perivascular regions in a subset of blood vessels (fig 1) . A second cohort of 13 patients with RA underwent arthroscopy before and 4 weeks after initiation of infliximab infusions. Patients had longstanding disease (mean disease duration 127 months, range 10-311), all were treated with MTX (mean dose 15 mg/week, range 5-30) and 10/13 with prednisolone (mean dose 9 mg/day, range 2.5-15). The 28-joint Disease Activity Score (DAS28) was significantly reduced following 4 weeks of infliximab therapy: DAS28 (median and IQR) at baseline, 6.25 (5.57-7.04); after 4 weeks, 4.48 (3.82-5.98) (p,0.01). However, there was persistent TWEAK expression after TNF blockade without any significant changes in ST TWEAK or Fn14 expression following infliximab therapy.
RESULTS
To rule out the possibility that the expression of TWEAK and Fn14 had been influenced considerably by disease duration or DMARD treatment in the above mentioned cohorts, ST samples from a third cohort of 6 recently diagnosed patients with RA who had not yet been treated with DMARDs was studied and compared to the 13 patients with RA from the second cohort. The expression of TWEAK and Fn14 was comparable between this group with early disease and the abovementioned group with longstanding disease before start of infliximab therapy, indicating that TWEAK and its receptor are expressed in early RA.
DISCUSSION
TWEAK and Fn14 are both abundantly expressed in the inflamed synovium of patients with (early) RA and PsA, where they may promote synovial inflammation and joint destruction. Of importance, there is persistent expression of TWEAK and its receptor after TNF blockade. TWEAK expression in the intimal lining layer and synovial sublining is significantly higher in RA compared to PsA, while Fn14 expression is similar. TWEAK and Fn14 are mainly expressed by FLS and, to a lesser extent, macrophages, suggesting that both effector cells may participate in TWEAK responses in patients with arthritis.
The TWEAK/Fn14 pathway appears to have a physiological role in the regulation of tissue repair after injury. TWEAK may initially be produced by tissue cells, and by invading inflammatory cells such as monocytes. The TWEAK-Fn14 pathway might then drive chemokine and cytokine production, resulting in additional infiltration of proinflammatory cells, and facilitate angiogenesis and the proliferation of progenitor cells needed for tissue repair. Chronic expression of TWEAK and Fn14 in inflammatory arthritis may subvert processes beneficial in acute tissue repair to pathogenic contributions. The expression of TWEAK and Fn14 in chronic synovitis could contribute to persistent inflammation and progressive destruction of the joint tissue by the production of chemokines, cytokines and MMPs, and promotion of cell proliferation and angiogenesis. Because the TWEAK/Fn14 pathway does not appear to be involved in the regulation of adaptive immunity, it has been suggested that blocking TWEAK/Fn14 activation would potentially have a favourable safety profile. Further studies are needed to identify the contributions of TWEAK/Fn14 to inflammatory arthritis, and the therapeutic potential of targeting this pathway.
